Showing 361 - 380 results of 10,368 for search '"database"', query time: 0.07s Refine Results
  1. 361

    Trends in stroke-related mortality in atrial fibrillation patients in the United States: Insights from the CDC WONDER database by Muhammad Abdullah Naveed, Sivaram Neppala, Himaja Dutt Chigurupati, Muhammad Omer Rehan, Ahila Ali, Hamza Naveed, Bazil Azeem, Rabia Iqbal, Manahil Mubeen, Mashood Ahmed, Ayman R. Fath, Timir Paul, Bilal Munir

    Published 2025-01-01
    “…Methods: A retrospective analysis was conducted to acquire death data using the Centers for Disease Control and Prevention database from 1999 to 2020. Age-adjusted mortality rates (AAMRs) were calculated per 100,000 persons, and trends were assessed using Average Annual Percentage Change (AAPC) and annual percent change (APC). …”
    Get full text
    Article
  2. 362

    Persistence of newly prescribed 5-aminosalicylic acid in patients with ulcerative colitis: A nationwide comprehensive database study. by Tatsuya Noda, Kotaro Kuwaki, Munehito Machida, Yasuyuki Okumura, Yuichi Nishioka, Tomoya Myojin, Tomoaki Imamura

    Published 2024-01-01
    “…This was a 1-year, nationwide, population-based cohort study using the National Database of Health Insurance Claims and Specific Health Checkups of Japan. …”
    Get full text
    Article
  3. 363
  4. 364
  5. 365

    The influence of baseline platelet on mortality risk in stroke and cancer patients: a cross-sectional analysis of the NHANES database by Yuqi Pei, Wei Ouyang, Peiyun Qi, Zhongjie Yan, Yaoru Li, Xiangjian Zhang, Cong Zhang, Lili Cui

    Published 2025-01-01
    “…Methods Participants with a history of stroke and cancer were selected from the database of the National Health and Nutrition Examination Survey from 2007 to 2018. …”
    Get full text
    Article
  6. 366

    Clinical and Cost Burden of Primary Sjögren’s Syndrome: Descriptive Analysis Using a US Administrative Claims Database by Sue Perera, Liyuan Ma, Raj Punwaney, Sulabha Ramachandran

    Published 2018-02-01
    “…**Methods:** This was a retrospective cohort study (HO-15-16077) conducted in the US Truven MarketScan Commercial database. We report descriptive data from employees and their families, as covered by employer-sponsored medical insurance. …”
    Get full text
    Article
  7. 367
  8. 368
  9. 369

    Clinicopathological Features, Treatment Strategy, and Prognosis of Primary Non-Hodgkin’s Lymphoma of the Duodenum: A SEER Database Analysis by Guoliang Zheng, Yue Wang, Yan Zhao, Zhichao Zheng

    Published 2020-01-01
    “…The Surveillance, Epidemiology, and End Results (SEER) database was queried from 1998 to 2015. Results. A total of 1060 cases of PDLs were identified. …”
    Get full text
    Article
  10. 370

    An organic matter database (OMD): consolidating global residue data from agriculture, fisheries, forestry and related industries by G. Weldesemayat Sileshi, G. Weldesemayat Sileshi, E. Barrios, J. Lehmann, J. Lehmann, F. N. Tubiello

    Published 2025-02-01
    “…Therefore, the objectives of the present work were to provide (1) definitions, typologies and methods to aid consistent classification, estimation and reporting of the various residues and by-products, (2) a global organic matter database (OMD) of residues and by-products from agriculture, fisheries, forestry and related industries and (3) regional and global estimates of residues and by-products potentially available for use in a circular bio-economy. …”
    Get full text
    Article
  11. 371
  12. 372
  13. 373

    Trends in survival of patients with stage I/II Burkitt lymphoma in the United States: A SEER database analysis by Ze‐Long Liu, Pan‐Pan Liu, Xi‐Wen Bi, De‐Xin Lei, Yu Wang, Zhi‐Ming Li, Wen‐Qi Jiang, Yi Xia

    Published 2019-03-01
    “…Due to limited information reported on survival trends of patients with stage I/II (limited‐stage) BL, here we used the Surveillance, Epidemiology, and End Results (SEER) database to conduct our study. The time period was divided into two eras (1983‐2001 and 2002‐2014) as the recent era reflected more intensive chemotherapy regimens, the availability of rituximab, the widespread use of antiretroviral therapy (ART) and improvements in supportive care. …”
    Get full text
    Article
  14. 374
  15. 375
  16. 376
  17. 377
  18. 378
  19. 379
  20. 380